115025-90-6 Usage
General Description
3-(2-Naphthalen-1-yl-ethyl)-3-[2-(tetrahydro-pyran-2-yl)-ethyl]-pentanedioic acid is a complex organic compound that belongs to the category of chemicals known as naphthalenes, which are structures with two fused benzene rings. Incorporating different ethyl groups and a pentanedioic acid group, its structure indicates that it may possess interesting chemical properties. The tetrahydro-pyran-2-yl group implies that this compound may also have significance in organic chemistry. The exact chemical properties, uses, and potential applications of this specific compound would depend on further laboratory analysis as its brief description doesn't provide in-depth detail about its functionality. At present, without specific data regarding its reactivity or potential applications, this compound is primarily of interest for theoretical syntheses and chemical analysis.
Check Digit Verification of cas no
The CAS Registry Mumber 115025-90-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,5,0,2 and 5 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 115025-90:
(8*1)+(7*1)+(6*5)+(5*0)+(4*2)+(3*5)+(2*9)+(1*0)=86
86 % 10 = 6
So 115025-90-6 is a valid CAS Registry Number.
InChI:InChI=1/C23H28O5/c24-21(25)15-23(16-22(26)27,13-11-19-8-4-14-28-19)12-10-18-7-3-6-17-5-1-2-9-20(17)18/h1-3,5-7,9,19H,4,8,10-16H2,(H,24,25)(H,26,27)
115025-90-6Relevant articles and documents
Practical access to four stereoisomers of naftidrofuryl and their binding affinity towards 5-hydroxytryptamine 2A receptor
Hao, Jia,Chen, Bo,Yao, Yiwu,Hossain, Murad,Nagatomo, Takafumi,Yao, Hequan,Kong, Lingyi,Sun, Hongbin
, p. 3441 - 3444 (2012/06/18)
Naftidrofuryl oxalate (Praxilene, 1) has been used for the treatment of intermittent claudication for more than 30 years. It selectively blocks vascular and platelet 5-hydroxytryptamine 2 (5-HT2) receptors. This drug is marketed as a mixture of four stereoisomers, and so far there is no individual biological evaluation on the single isomers. The purpose of this study is to provide an improved method for the preparation of all four stereoisomers of naftidrofuryl, and more importantly, to distinguish them in terms of their binding affinity to 5-hydroxytryptamine 2A (5-HT2A) receptor. The bioassay results revealed that the C-2S configuration of naftidrofuryl was crucial for the binding affinity with 5-HT2A receptor, and the C-2′ configuration was less important for binding. In conclusion, our study may pave the way to develop single naftidrofuryl isomers with C-2S configuration as inhibitors of 5-HT2A receptor that have clinical significance as vasodilators and CNS agents.
